5-氨基水杨酸在炎症性肠病中的应用

被引：25

作者：

李舒

李世荣

盛剑秋

机构：

[1] 北京军区总医院消化内科

来源：

胃肠病学 | 2016年 / 21卷 / 04期

关键词：

氨基水杨酸类; 炎症性肠病; 治疗;

D O I：

暂无

中图分类号：

R574.62 [结肠疾病];

学科分类号：

100201 [内科学];

摘要：

5-氨基水杨酸(5-ASA)为治疗炎症性肠病(IBD)的一线药物,其治疗轻、中度溃疡性结肠炎具有安全、有效、耐受性良好等特点。近年5-ASA新制剂和新剂型不断涌现,进一步扩大了治疗适应证。本文就各种5-ASA制剂的特点及其临床应用作一综述。

引用

页码：250 / 252

页数：3

共 11 条

[1]

王承党 ;

喻春梅 .

胃肠病学和肝病学杂志, 2013, 22 (04) :348-353

[2]

美沙拉嗪与柳氮磺吡啶比较治疗溃疡性结肠炎疗效与安全性的系统评价 [J].

柳汝明 ;

吴斌 ;

赵雨晋 ;

唐尧 .

中国循证医学杂志, 2011, 11 (02) :181-186

[3]

活动期溃疡性结肠炎活检黏膜的病理组织学特征、分级及其与疾病程度的关系 [J].

钟英强 ;

朱兆华 ;

幸连春 .

中华消化杂志, 2003, (07)

[4]

A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease [J].

Yang, Zhiping ;

Ye, Xiaofei ;

Wu, Qiong ;

Wu, Kaichun ;

Fan, Daiming .

INTERNATIONAL JOURNAL OF SURGERY, 2014, 12 (05) :516-522

[5]

Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system [J].

Khan, N. ;

Abbas, A. M. ;

Bazzano, L. A. ;

Koleva, Y. N. ;

Krousel-Wood, M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (08) :755-764

[6]

Purine analogues compared with mesalamine or 5-ASA for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis [J].

Shen, F. -C. ;

Zhang, H. -J. ;

Zhao, X. -D. ;

Cao, R. -S. ;

Shi, R. -H. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (08) :758-766

[7]

One‐year investigator‐blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.[J].A. Barney Hawthorne;Rachel Stenson;David Gillespie;Edwin T. Swarbrick;Anjan Dhar;Kapil C. Kapur;Kerry Hood;Chris S.J. Probert.Inflamm Bowel Dis.2011, 10

[8]

Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort [J].

Froslie, Kathrine Frey ;

Jahnsen, Jorgen ;

Moum, Bjorn A. ;

Vatn, Morten H. .

GASTROENTEROLOGY, 2007, 133 (02) :412-422

[9]

MMX Multi Matrix System<sup>?</sup> mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized; double‐blind; placebo‐controlled trials.[J].W. J.SANDBORN;M. A.KAMM;G. R.LICHTENSTEIN;A.LYNE;T.BUTLER;R. E.JOSEPH.Alimentary Pharmacology & Therapeutics.2007, 2

[10]

Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis.[J].E. V.Loftus;S. V.Kane;D.Bjorkman.Alimentary Pharmacology & Therapeutics.2004, 2

← 1 2 →